Case Study

US commercialisation strategy for target asset

OPPORTUNITY ASSESSMENT

THE CLIENT

A Chinese Biotech, with an internal drug discovery platform, looking to expand their portfolio within China and the US. The company has an interest in investment and licensing opportunities in China (and potentially globally) to further establish their footprint as a global player in oncology

THE BUSINESS CHALLENGE

The client wanted to in-license a novel MOA asset that could target certain virally-induced cancers. They sought help with performing due diligence on the asset with regards to the US market opportunity

OUR APPROACH

We performed an independent assessment of multiple potential indications for the novel MOA asset via primary and secondary research

THE RESULTS

Our assessment and recommendations informed indication selection and sequencing for the novel MOA asset that would minimise risk and optimise market potential. In addition, we identified potential clinical development strategies in the US that could synergize with the client’s development in China. We provided an outlined context of development in China vs. US, providing strong guidance for a deal sheet & Business Development strategy